Human anti-IL-6 Receptor (Sarilumab) mAb

Synonyms:

REGN88, SAR153191, Kevzara

Species:

Human

Cat. No.:

CSB113A pdf (datasheet)

Quantity/Size:

100 µg

Price:

$470.00 BUY

Concentration:

1.0 mg/ml

Description:

Sarilumab is a fully human anti-IL-6R monoclonal IgG1 antibody that binds to both membrane bound and soluble interleukin 6 (IL-6) receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developped by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe Rheumatoid Arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis and its treatment has been challenged by the different response in every patient. Subcutaneous administration of Sarilumab has been shown to decrease acute-phase reactant levels and improve in clinical RA symptoms.

Entrez Symbol:

IL6R

Uniprot ID:

P08887

Purity:

> 95% as determined by SDS-PAGE

Specificity:

Human soluble and membrane-bound IL-6R

Host Species:

Human

Isotype:

IgG1 Kappa light chain

Formulation:

PBS, pH 7.5

Application:

ELISA, FS

Storage/Stability:

Store at -20°C to -80°C for up to 1 year.